Sunshine Biopharma (SBFM) announced that its wholly owned Canadian subsidiary, Nora Pharma, has launched NIOPEG, the company’s first Biosimilar drug on the market. NIOPEG is a Biosimilar comparable to the reference biologic drug NEULASTA. Like NEULASTA, NIOPEG is a long-acting, pegylated form of recombinant human granulocyte colony-stimulating factor. It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving chemotherapy. NIOPEG is available in a prefilled syringe of 6mg/0.6mL.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBFM: